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This study was performed to assess the efficacy and safety of docetaxel, cisplatin and fluorouracil combination in patients with
unresectable locally advanced oesophageal squamous cell carcinoma. Treatment consisted of docetaxel 60mgm
 2, cisplatin
75mgm
 2 on day 1 and fluorouracil 750mgm
 2day
 1 on days 2–5, repeated every 3 weeks for three cycles, followed by
carboplatin 100mgm
 2week
 1 for 5 weeks and concurrent radiotherapy (45Gy in 25 fractions, 5daysweek
 1). After radiotherapy,
eligible patients either underwent an oesophagectomy or received high dose rate endoluminal brachytherapy (HDR-EBT). Thirty-one
out of 37 enrolled patients completed the planned chemotherapy and 30 completed chemoradiation. After completion of
chemotherapy, 49% (95% CI: 32.2–66.2) had a clinical response. Twelve patients (32%) underwent a resection, which was radical in
60% (postoperative mortality: 0%). A pathological complete response was documented in four patients (11% of enrolled, 30% of
resected). The median survival was 10.8 months (95% CI: 8.1–12.4), and the 1- and 2-year survival rates were 35.1 and 18.9%,
respectively. Grade 3–4 toxicities were neutropoenia 32%, anaemia 11%, non-neutropoenic infections 18%, diarrhoea 6% and
oesophagitis 5%. Nine patients (24%) developed a tracheo-oesophageal fistula during treatment. Even if the addition of docetaxel to
cisplatin and 5-fluorouracil (5-FU) seems to be more active than the cisplatin and 5-FU combination, an incremental improvement in
survival is not seen, and the toxicity observed in this study population is of concern. In order to improve the prognosis of these
patients, new drugs, combinations and strategies with a better therapeutic index need to be identified.
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Oesophageal cancer is the sixth leading cause of death from cancer
worldwide (Pisani et al, 1999) and its fatality rate at 5 years reaches
90% (Blot and McLaughlin, 1999). The prognosis remains dismal
because, at diagnosis, surgery is inappropriate in 40–60% of
patients owing to unresectable primary disease, distant metastases
or high operative risk (Sagar et al, 1994).
Of those undergoing operation, between 55 and 80% will have a
‘potentially’ curative resection (Muller et al, 1990; Sagar et al,
1994), which is safe only in experienced hands (Siewert et al, 2001).
With radiotherapy alone these results did not improve, and
5-year survival rates remain o10% (al-Sarraf et al, 1997).
Chemotherapy can provide significant palliation of symptoms for
patients with unresectable, locally advanced or metastatic disease.
The repertoire of chemotherapeutic agents with activity against
squamous cell carcinoma (SCC) is restricted, but responses have
been documented in studies utilising cisplatin, 5-fluorouracil (5-
FU), vindesine, mytomicin, paclitaxel and vinorelbine (Enzinger
et al, 1999). In the multi-modality treatment of oesophageal
cancer, cisplatin and continuous-infusion 5-FU (PF), alone or
combined with radiotherapy, is the most frequently used regimen
(Cooper et al, 1999).
The response rate reported with PF ranged from 35 to 40% (De
Besi et al, 1986; Bleiberg et al, 1997; Ancona et al, 2001), whereas
the 2-year survival rates of patients with locally advanced
oesophageal cancer ranged from 8 to 55%, with a mean 27%. A
better prognosis with chemoradiotherapy/chemotherapy (al-Sarraf
et al, 1997; Stuschke et al, 2000; Kodaira et al, 2003; Polee et al,
2003) has been reported, but these series also included patients
with potentially resectable carcinomas.
The majority of studies on combined therapy showed longer
survival for patients achieving a pathologic complete response
(pCR), which can be obtained in 12–40% of patients treated with
PF combined therapy (Forastiere et al, 1997; Ancona et al, 2001).
Patients with a less advanced stage are more likely to achieve a
pCR than those with a more advanced disease (Rohatgi et al, 2005).
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sTherefore, there is a need to test new combinations, specifically
in unresectable locally advanced oesophageal patients, with the
aim of increasing the pCR rate and survival.
The mechanism of action of docetaxel is different from that of
PF and has proved to have an additive effect with cisplatin and
supra-additive antitumour activity with fluorouracil in vitro and in
murine models of xeno-grafted human tumours (Burris et al, 1992;
Catimel et al, 1994; Dreyfuss et al, 1996). Docetaxel has been
shown to be more active than paclitaxel in 10 oesophageal cancer
cell lines (Kawamura et al, 1997) and clinically active in patients
with oesophageal adenocarcinoma (Einzig et al, 1996). Further-
more, its combination with cisplatin, fluorouracil and leucovorin
showed an overall response (OR) of 94% and a complete response
(CR) of 44% in patients with SCC of the head and neck, without
altering the ability to administer definitive radiotherapy (Colevas
et al, 1998).
It seemed therefore appropriate to evaluate, in a phase II study,
the combination of docetaxel, cisplatin and fluorouracil (DCF) in
patients with locally advanced oesophageal SCC.
Italian patients with oesophageal SCC are heavy smokers and
drinkers, and often present vascular and peripheral nerve
impairment from this abuse. Therefore, we chose to use
carboplatin instead of cisplatin during radiotherapy, as continuous
carboplatin infusion during radiotherapy has been shown to be
cytotoxic as cisplatin in human lung cancer cell lines (Groen et al,
1995a), and active, while less nephro- and neurotoxic, in non-
small-cell lung and head and neck cancer patients (Groen et al,
1995b; Loreggian et al, 1997).
The study reported here is a prospective phase II trial of DCF,
followed by external beam radiotherapy concurrent with contin-
uous carboplatin infusion, designed to evaluate the activity of DCF
in patients with locally advanced oesophageal SCC.
Secondary objectives were safety of the combination, the pCR
rate in operable patients, local and systemic recurrence and
median and overall survival.
PATIENTS AND METHODS
Eligibility and pretreatment evaluation
Before entry into the study, all patients were evaluated by a
multidisciplinary team, which included a medical oncologist, a
radiation therapist, a surgeon and a gastroenterologist. Eligibility
criteria were age o75 years, histologically proven and previously
untreated SCC of the oesophagus, WHO performance status (PS)
p2, absolute neutrophil count X2 10
9l
 1, platelet count
X100 10
9l
 1, and adequate renal and hepatic function. Exclu-
sion criteria were evidence of distant metastases, pleural or
pericardial effusion, fistulisation, prior malignancies (other than
basal cell skin carcinoma), prior myocardial infarction or
uncontrolled infections. All patients were required to give written
informed consent before entering the study, which was approved
by the Ethics Committee of the two participating centres.
Pretreatment evaluation included a medical history, physical
examination (PE), complete blood cell count and serum chemistry
tests; barium oesophagram; oesophagoscopy; bronchoscopy; en-
doscopic ultrasound (EUS); computed tomography (CT) scans of
the chest and abdomen; cervical US with fine-needle aspiration
biopsy of suspicious nodes.
Based on the results of the EUS, patients were assigned a
preoperative clinical stage according to the 1997 TNM classifica-
tion of the International Union Against Cancer (Sobin, 1997). In
case of a discrepancy between the CT and EUS findings, we
classified the patient according to the worst stage. Only those
patients with T3–4 or N1 or M1 (nodal) disease, unresectable for
tracheobronchial infiltration, or an M1a nodal extension, or
laryngeal nerve palsy were eligible for this study. One patient
with a T2 N1 tumour was also considered eligible owing to the
cervical location.
Treatment plan
Treatment consisted of docetaxel 60mgm
 2, as a 1-h infusion,
with 500ml normal saline on day 1 of a 21-day cycle. Cisplatin
75mgm
 2 was given 1h after the completion of docetaxel over
30min with a 2l fluid pre-hydration (0.9% salineþ30ml of 10%
KClþ12ml of 10% MgCl2), followed by a 1.5l fluid post-hydration
(0.9% salineþ30ml of 10% KClþ12ml of 10% MgCl2). Fluoro-
uracil 750mgm
 2day
 1 was given by intravenous (i.v.) continuous
infusion on days 2–5.
Blood products, nutritional support and all other means of
symptomatic relief were allowed according to each patient’s needs.
Granulocyte colony-stimulating factor, 300mgday
 1 subcuta-
neously, was allowed only in case of neutropoenic fever.
Dose modifications were planned as follows: for haematological
toxicity consisting of absolute neutrophil count (ANC) less than
1500cellsmm
 3 or platelet count less than 100000cellsmm
 3 on
day 1, delay of DCF for 1 week; reduction of the dose of all drugs
to level –1 ( 25%) for ANC o500 cellsmm
 3, without fever, or
platelet count o50000cellsmm
 3 without bleeding, or grade 3
mucositis according to the National Cancer Institute common
toxicity criteria (NCI-CTC, version 2.0), and to level  2(  40%)
for ANC o500cellsmm
 3 with fever, or platelet count
o50000cellsmm
 3, with bleeding, or grade 4 mucositis; reduction
of cisplatin to level –1 for grade 2 renal toxicity and reduction to
level –2 for grade 3 renal toxicity.
Interval assessments during the treatment included PE, nutrition
evaluation, weekly complete blood cell count with differential and
platelet count, and renal and liver function tests every 3 weeks.
Radiation therapy was administered with a high-energy linear
accelerator at 6–20mV. The treatment volume included the area of
the primary tumour and potential sites of lymphatic involvement.
The planned target volume for carcinoma of the upper or middle
third oesophagus included the primary tumour with a 5-cm
longitudinal margin, metastatic nodes with a 2-cm margin,
supraclavicular fossa and mediastinum. For carcinoma of the
lower third oesophagus, the field was extended to include both
the peri-gastric and celiac nodes. The dose was prescribed to the
isodose line, which covered the volume at risk. A daily dose of
1.8Gy was given up to a dose of 30.6Gy. The radiation portals were
then changed to encompass the primary tumour and metastatic
nodes with a 2-cm margin lesion up to a final dose of 45Gy. The
radiation dose to the spinal cord was maintained at a maximum of
45Gy.
Carboplatin, 100mgm
 2week
 1 i.v. continuous infusion, was
concurrently administered with radiotherapy for 5 weeks by an
elastomeric infusion pump through a central venous access
catheter. Radiation therapy and carboplatin were withheld only if
the ANC was o500 or the platelet count o25000.
Patients who were unable to maintain their weight were started
on enteral or parenteral feeding. Patients were withdrawn from the
study if they presented progressive disease, life-threatening
toxicities, fistulisation or expressed their desire to withdraw.
Surgery, brachytherapy and staging criteria
Toxicity was graded using the NCI-CTC version 2.0. All events that
occurred during the treatment or worsened in comparison with
baseline scores were considered toxic.
Patients were restaged 4 weeks after the third DCF cycle and 4–6
weeks after completion of chemoradiation, repeating the pretreat-
ment staging work-up. Clinical CR was defined as a complete
symptomatic, radiographic and endoscopic normalisation.
Definition of a clinical partial response (PR) was more difficult;
we defined PR as a reduction from the initial clinical stage (AJCC,
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s1997) (Fleming, 1997), determined by a compilation of results from
the CT scans, EUS, barium oesophagram and endoscopy.
Stable disease (SD) was defined as no change in the TNM stage,
and progressive disease (PD) as an increase in the TNM stage or
by the discovery of new metastatic lesions at any time. Patterns of
failure were defined as the first site of failure. Local failure
included the primary tumour and local/regional lymph nodes.
Distant failure included any other site of disease recurrence.
Dysphagia was scored before the treatment and at each subsequent
PE, using a published dysphagia scale (Knyrim et al, 1993): a score
of 0 denoted no dysphagia; 1, trouble in swallowing solids; 2,
the ability to swallow semi-solids alone; 3, the ability to
swallow liquids alone; and 4, complete dysphagia to solids and
liquids.
Patients who obtained a CR or a PR were offered an Ivor-Lewis
oesophagectomy. Resection and reconstruction were accomplished
using simultaneous right thoracotomy and midline laparotomy.
For cervical and upper thoracic lesions, a concomitant pharyngo-
laryngectomy was carried out together with a three-field lympha-
denectomy. Pathological complete remission (pCR) was defined as
the absence of residual tumour in the resected oesophageal and
nodal specimen (pT0N0). Patients who refused or were considered
unfit for surgery were offered a high dose rate endoluminal
brachytherapy (HDR-EBT) boost with the aim of improving local
control. High dose rate endoluminal brachytherapy was performed
once weekly for 3 consecutive weeks and started 2–4 weeks after
chemotherapy and radiotherapy completion, to allow resolution
qof oesophageal mucositis. A radio-opaque clip was placed on the
oesophageal mucosa, 1cm above the tumour bed, via endoscopy.
This device substantially facilitates the radiological localisation of
the tumour bed when positioning the applicator charged with a
dummy source. The mean total dose was 15Gy, 5Gy per session,
prescribed at 0.6cm from the surface of a flexible applicator with
a diameter of 0.8cm. The active length, planned at the time of
endoscopy, was the visible mucosal tumour with a 2cm distal and
proximal margin, without optimisation.
Statistical methods
The primary outcome of this study was the OR rate, defined as the
proportion of responders (complete or partial) among all patients,
of the DCF combination in locally advanced oesophageal SCC
patients. The sample size was calculated based on the assumption
that a 40% OR rate or less was considered insufficient to warrant
further investigation. On the other hand, a probability of response
above 60% would be clinically sufficient and indicates that further
investigation of this regimen is appropriate. The accrual consisted
of two stages according to Simon (1989).
This design minimises the expected number of treated patients,
if the response rate is inadequate. If seven or less responses were
observed in the first 19 patients, the study would have been
terminated. In the case of eight or more responses in these 19
patients, 15 additional patients would have been enrolled. If more
than 16 responses were observed among all of the 34 patients, the
treatment would be considered active. This scheme ensured that
the chance of erroneously rejecting the treatment is less than 10%
if the treatment is active in at least 60% of the patients, whereas the
probability of erroneously recommending a treatment whose
response rate is inadequate is limited to 15%. Confidence intervals
were adjusted for the two-stage design (Atkinson and Brown,
1985). Secondary end points were the pathological remission rate,
the toxicity rate, dysphagia response and survival times.
Survival times were calculated from the beginning of chemo-
therapy to the date of death, progressive disease or to last follow-
up. The Kaplan–Meier method was used to estimate the survival
curves.
Actual dose intensity was calculated as recommended by
Hryniuk and Goodyear (1990).
Analyses were performed using the SAS statistical package (SAS,
release 8.02, Cary, NC, USA)
RESULTS
Patient characteristics
Between July 1998 and February 2002, 37 patients were enrolled in
the study at two Italian oncology centres: the Medical Oncology
Unit of the Istituto Oncologico Veneto, Padova and the Centro di
Riferimento Oncologico, Aviano. Characteristics of the 37 patients
are listed in Table 1. The median age was 61 years (range, 39 – 72
years), and 62% of patients had a WHO PS of 2.
Twenty-six patients had T4 disease, 31 had mediastinal, two
coeliac and three cervical node metastases; one patient had
unsuspected bone metastasis. Twenty-five primary tumours were
in the upper–mid-thoracic oesophagus, four in the cervical, two in
the lower thoracic and six patients had more than one location. All
patients had dysphagia before treatment: four (11%) grade 1; 16
(43%) grade 2; 11 (30%) grade 3; six (16%) grade 4 and almost 50%
of patients had suffered a weight loss X10%. According to Simon’s
design, 19 patients entered the first stage of study . Fifteen patients
were required for the second stage. As it was expected that some
patients might not be fully evaluable, 37 patients were finally
recruited.
Response and dysphagia relief
Response results are summarised in Table 2. Among the first 19
patients, 10 responses were observed. The OR rate, on an
intention-to-treat analysis, was 48.6% (18 of 37 patients) (95%
adjusted CI: 32.2 – 66.2%). Six patients (16%) had a CR with
negative biopsies, 12 (32%) obtained a PR, seven patients (19%)
remained stable, eight (22%) had PD and four (11%) early death.
After carboplatin infusion and radiotherapy, two patients had a
further reduction of disease, 20 remained stable and eight had
progressive disease. All patients reported some grade of dysphagia
on trial entry. Median baseline score was 2 (range 1–4). After
induction chemotherapy, dysphagia improved by at least one level
in eight patients (22%) and completely resolved in 12 patients
(32%), with an overall improvement in dysphagia in 54% of
Table 1 Patient characteristics
Characteristics No. of patients %
Total 37
Age (years)
Median (range) 61 (39–72)
Gender
Male 29 78
Female 8 22
ECOG
a performance status
11 4 3 8
22 3 6 2
Clinical stage
T2 N1 1 3
T3 N1 5 13
T4 N0–1 26
b 70
T3–4 N0–1 M1a 5 14
Tumour location
Cervical 4 11
Upper-middle 25 68
Lower 2 5
More than one site 6 16
Weight loss 410% 18 49
aECOG¼Eastern Cooperative Oncology Group.
bOne of these patients had bone
metastases.
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spatients. Dysphagia worsened in eight (22%) and six required
placement of an enteral feeding tube for nutritional support. Nine
(24%) developed a tracheo-oesophageal fistula, four during
induction therapy and five during or at the end of radiotherapy.
Surgery and brachytherapy
Of the 12 patients who underwent surgery, seven (58%) had a
complete surgical resection with clear margins, two had a
macroscopic clearance but positive resection margins on histolo-
gical assessment, three had a macroscopically incomplete resection
owing to tumour adherence to the trachea in two and to the aorta
wall in one. There were no postoperative deaths and a pCR was
documented in four patients (30% of resected and 10.8% of
enrolled, respectively).
All the seven patients treated with HDR-EBT recurred locally.
Toxicity and treatment delivery
Toxicity data are available for all patients. The most frequently
encountered toxicities were leucopoenia (38% grade III/IV),
neutropoenia (32% grade III/IV), anaemia (11% grade III/IV),
mucositis (35% grade II and 5% grade III), non-neutropoenic
infections (13% grade III/IV) and diarrhoea (6% grade III/IV)
(Table 3). All patients experienced grade II alopecia. One patient
died of a cerebral stroke (3% grade IV). Among the non-
neutropoenic infections, we observed two, non-fatal, mycotic
pneumonitis. Two fatal mediastinitis, due to a fistulisation,
occurred immediately after the first cycle. One patient died after
the third cycle owing to a neutropoenic fever and diarrhoea.
The cycles delivered were 103 over 111 planned; delays in
chemotherapy owing to toxicity were required in three patients,
with a maximum delay of 14 days. No dose reductions were made.
The planned dose intensity was 20mgm
 2week
 1 for docetaxel,
25mgm
 2week
 1 for cisplatin and 750mgm
 2week
 1 for fluoro-
uracil.
The median percentage of dose intensity delivered was 96% for
docetaxel, 98% for cisplatin and 98% for fluorouracil (Table 4).
The main toxicity during chemoradiotherapy was grade III and
IV oesophagitis in 73% of patients. All patients received the
planned weekly dose of carboplatin without delay and/or evidence
of haematological toxicity. Thirty patients received the carbo-
platine-radiotherapy segment with a mean total radiation dose of
45Gy (range 30–60Gy). One patient stopped XRT after 30Gy
owing to the occurrence of a tracheo-oesophageal fistula and two
patients continued to 60Gy because they were unfit for surgery.
After carboplatin and radiotherapy, 18 downstaged patients
were referred to the surgeon: 12 were operated, one refused and
the remaining five were considered medically unfit for surgical
resection. These six patients and one with a cervical tumour
location were treated with HDR-EBT.
Two patients died of a myocardial failure 225 and 479 days from
the start of therapy, one of them without evidence of disease.
Survival and pattern of failure
The median survival was 10.8 months (95% CI: 8.1–12.4), and
1- and 2-year survival rates were 35.1% (95% CI: 20.4–50.2) and
18.9% (95% CI: 8.3–32.8) (Figure 1). Currently, of 37 DCF-treated
patients, four (11%) are alive and disease-free, with a minimum
follow-up of 50 months. Fifteen out of the 18 responding patients
progressed or relapsed. The median time to progression was 9.8
months (95% CI: 8.5 – 16.0) and 1- and 2-year progression-free
survival rates were 38.9% (95% CI: 17.5 – 60.0) and 22.2% (95% CI:
6.9 – 42.9), respectively (Figure 2). The median survival of DCF
responding patients was 14.7 months (95% CI: 11 – 24.7) vs 6.6
months (95% CI: 3.9 – 9.8) of non-responding.
Thirty patients are evaluable for progression site: 10 patients
(33.3%) had a local progression, four (13.3%) had distant
metastases without local recurrence and 16 (53.3%) had both.
Table 2 Response rate to chemotherapy
DCF
a response
Responses No. of patients % 95% CI
Overall response 18 49 32–66
Complete response 6
Partial response 12
Stable disease 7 19
Progressive disease 8 22
Early death 4 11
aDocetaxel, cisplatin and fluorouracil. CI¼confidence interval.
Table 3 Docetaxel, cisplatin and fluorouracil chemotherapy toxicity
Common toxicity criteria (%) (no.¼37)
Toxicities Grade 1 Grade 2 Grade 3 Grade 4
Leucopoenia 39 19 27 11
Neutropoenia 29 19 24 8
a
Thrombocytopoenia 8 8 5 0
Anaemia 46 22 8 3
Mucositis 27 35 5 0
Alopecia 0 100 0 0
Nausea and vomiting 19 13 3 0
Diarrhoea 0 0 3 3
Hepatic 3 0 0 0
Infection 0 0 3 8
Cerebrovascular 0 0 0 3
a
Fistula 0 0 0 11
a
aToxic deaths occurred in four patients.
Table 4 Dose of docetaxel, cisplatin and fluorouracil and actual dose intensity
Docetaxel Cisplatin Fluorouracil
Median (range) Median (range) Median (range)
Target dose (mgm
 2) 180 225 9000
mgm
 2 received 176.5 (59.2; 218.2) 222.8 (68.2; 226.7) 8977.5 (2574.0; 9069.8)
Target DI,
a mgm
 2week
 1 20 25 1000
Actual DI, mgm
 2week
 1 19.3 (10.7; 24.0) 24.6 (3.3; 29.2) 984.4 (333.7; 1176.7)
% of target DI 0.96 (0.53; 1.20) 0.98 (0.13; 1.17) 0.98 (0.33; 1.18)
aDI¼dose intensity.
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sThe most frequent sites of distant metastases were lungs (11
patients), bone (five), cutis and subcutis (three).
DISCUSSION
In this population of locally advanced oesophageal SCC patients,
DCF showed substantial activity in the treatment of oesophageal
cancer. The 49% response rate observed is higher than that
reported with cisplatin and 5-FU alone (De Besi et al, 1986;
Bleiberg et al, 1997), which is still considered the standard
treatment.
In the last decade, several attempts have been made to test new
agents, especially taxanes, topoisomerase I inhibitors and vino-
relbine. However, differences in the study population make the
comparison difficult, as some studies had included both locally
advanced tumours and metastatic disease, or metastatic disease
alone, and others had included both adenocarcinoma and SCC.
Despite a similar chemosensitivity reported for adenocarcinoma
and SCC (Ilson et al, 1997), the adenocarcinoma tumour type was
an independent prognostic parameter in a large Western world
series (Siewert et al, 2001).
Paclitaxel used alone at different doses or combined with
cisplatin gave an RR of 14.5–50% (Ajani et al, 1994; Kelsen et al,
1997; Petrasch et al, 1998) with a treatment-related mortality of
10% and hospitalisation owing to toxicity in 50% of the patients.
Irinotecan was evaluated in combination with cisplatin in a
weekly schedule, reporting 20 responses in 35 patients (57%) in the
first publication, although in a subsequent publication from the
same author, only 10 (36%) confirmed major responses were
reported (Ilson et al, 1999; Ilson, 2004).
Irinotecan was also combined with docetaxel, obtaining an RR
of 30 %, in metastatic patients, with an extremely high incidence of
febrile neutropoenia (43%) (Govindan et al, 2003).
The combination of vinorelbine and cisplatin was tested only in
metastatic patients, obtaining an RR of 34% with acceptable
toxicity (Conroy et al, 2002).
Docetaxel alone was tested in 52 metastatic patients, obtaining
an RR of 20% with a median survival time of 8.1 months; febrile
neutropoenia was the main toxicity and was observed in 18% of
the patients (Muro et al, 2004). Docetaxel was also investigated
in combination with cisplatin, obtaining four responses out of 10
patients with metastatic SCC (Laack et al, 2005) and in
combination with capecitabine, obtaining 11 responses out of 24
patients with metastatic disease (Lorenzen et al, 2005).
The combination of docetaxel, cisplatin and 5-FU, evaluated
in recurrent and previously treated patients, achieved major
responses in four out of 10 patients; however, a grade 3/4
leukopoenia occurred in eight of them (Tanaka et al, 2003).
Our study is the first to test this combination in a homogenous
population of previously untreated squamous oesophageal carci-
noma patients, even if characterised by poor prognostic char-
acteristics: 62% of patients had a grade 2 WHO PS, 84% had nodal
involvement, 14% had non-regional lymph node metastases (M1a)
and 89% had a primary lesion located above the carina. The
median survival expected with palliative treatment as radiotherapy
or intubation with self-expanding stents in these patients is only
3–6 months (Knyrim et al, 1993). The RR of 49% and the median
survival of 10.8 months, with an improvement of dysphagia in
more than 50% of patients, and a 1- and 2-year survival of 35 and
19%, clearly suggest that DCF combination is active, that
chemoradiotherapy is the best palliation for patients with
inoperable locally advanced oesophageal SCC and that this
approach might be curative in some.
The treatment of these patients presents significant clinical
problems related not only to the extension and location of disease,
but also to their poor clinical and nutritional status owing to the
long use of tobacco and alcohol, and made worse by the feeding
impairment, resulting in an increase in complications, as well as
toxic and early deaths. These complications are more frequent
in SCC than in adenocarcinoma patients, as observed by others
(Adelstein et al, 2000). In our study, the early deaths, partly related
to disease complications and partly related to treatment toxicity,
were 10.8%. This clearly disappointing percentage is inferior to
the 18% reported by Adelstein et al (2000) with a paclitaxel
combination, and has been previously reported in oesophageal
cancer, even in patients with a less advanced stage of disease
(Bleiberg et al, 1997; Wright et al, 1997). We observed that only
patients with a WHO PS of 2 developed fatal toxicity; therefore,
careful patient selection, improvement in liquid and nutritive
intake, as well as the prophylactic use of antibiotics could be
beneficial and recommendable before starting therapy. The high
percentage of fistulisation observed might be explained by the
prevalence of T4 lesions, localised mostly in the upper or middle
portion of the oesophagus. The high risk of treatment-related
perforation of the oesophageal wall in T4 oesophageal patients
was also highlighted by Ohtsu et al (1999). In order to reduce the
perforation risk, we decided to use induction chemotherapy,
before chemoradiotherapy, with the hope of decreasing the tumour
volume before encountering severe oesophagitis and stomatitis.
Unfortunately, this strategy seemed to be ineffective, even if the
dysphagia improved in the majority of patients.
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more effective in preventing this complication; however, it was
inapplicable in some patients owing to the extension or the
location of the lesion, was not accepted by others and, moreover,
might have interfered with the subsequent response evaluation. A
change in the chemotherapy schedule, like the use of weekly doses,
might help to reduce the acute tumour necrosis and permit wall
repair (Ilson et al, 2003).
In this study, only five patients had M1 disease, making a
comparison between them and other patients inadequate. How-
ever, it should be pointed out that three of them responded to the
treatment, one obtained a pCR and another is one of the four long
living. These findings are similar to the results reported by Ohtsu
et al (1999)) and Polee et al (2003)) and support the concept that
chemoradiotherapy has the same curative potential, for locally
advanced disease, irrespective of mediastinal or M1a node
extension; therefore, separating these groups is not strictly
necessary. The utility of surgical resection after chemoradiother-
apy in advanced oesophageal cancer is still not established; in spite
of this, we offered responding patients the possibility of resection,
as this was the best way to ascertain the rate of complete response,
and residual tumour resection could be beneficial. Currently, only
radically resected patients are long survivors in our study, despite
evidence of residual tumour in three of them.
This result, together with that of others, seems to imply that
surgical resection could be useful at least in some patients
(Adelstein et al, 2000; Ilson et al, 2003). No conclusions can be
drawn on the utility of HDR-EBT in the local control of disease
from our data, as few patients received this treatment. We can,
however, say that the planned dose of 15Gy in three fractions was
well tolerated with minimal acute effects, even if all patients
progressed. Local recurrences (87%), all within the radiation field,
remain the most important cause of death. We can argue that the
dilation of radiotherapy and its combination with carboplatin
alone could have hampered the adequate local control of the
disease. Nevertheless, a similar rate (77%) of local failure was
reported by Ohtsu et al (1999) who delivered a total dose of 60Gy
concomitant with PF, followed by two more courses of PF alone.
Thus, this high rate of local recurrences is more likely related
to the advanced stage of the disease than to the dilation of
radiotherapy, or to the dose and schedule used.
Our results suggest that DCF is an active regimen with curative
potential in some patients with unresectable locally advanced
oesophageal SCC. However, survival is still disappointing and
not improved over standard cisplatin/5-FU regimens. The
toxicity observed in treating these patients is still relevant
and in someway might hamper the clinical efficacy. In order
to improve the prognosis of these patients, new drugs, combina-
tions and strategies with a better therapeutic index need to be
identified.
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